Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 8/20 | 0.54 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.47 |
| ▸ | CCR2 | P41597 | 4/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1811117 | 0.93 | ACLY (0.47) | ACLYBRD4PTGES2CCR2KIT | |
| SCHEMBL3906639 | 0.92 | ACLY (0.54) | ACLYBRD4PTGES2 | |
| SCHEMBL3906066 | 0.86 | ACLY (0.43) | ACLYBRD4CCR2SLC40A1 | |
| SCHEMBL3902067 | 0.86 | ACLY (0.53) | ACLYBRD4CCR2 | |
| SCHEMBL1810122 | 0.84 | BRD4 (0.44) | ACLYBRD4CCR2 | |
| SCHEMBL3917122 | 0.83 | NR1I2 (0.45) | BRD4SLC40A1 | |
| SCHEMBL1811881 | 0.83 | PTGES2 (0.46) | ACLYBRD4PTGES2 | |
| SCHEMBL1818133 | 0.81 | PKM (0.43) | BRD4SLC40A1 | |
| SCHEMBL3906458 | 0.81 | ACLY (0.47) | ACLYCCR2 | |
| SCHEMBL1811874 | 0.81 | DAO (0.38) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101027286-B | Indazolone derivatives as 11b-HSD1 inhibitors | HOFFMANN LA ROCHE | 2011-05-25 | — | — | CN | claimed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | claimed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | claimed |
| CN-101027286-A | Indazolone derivatives as 11 b-HSD 1 inhibitors | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | CN | claimed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | claimed |
| CN-101027286-B | Indazolone derivatives as 11b-HSD1 inhibitors | HOFFMANN LA ROCHE | 2011-05-25 | — | — | CN | disclosed |
| US-7528158-B2 | Indazolone derivatives useful as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1797042-B1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| CN-101027286-A | Indazolone derivatives as 11 b-HSD 1 inhibitors | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | CN | disclosed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | ACLY 2238/4885BRD4 2606/4885PTGES2 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.